Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what’s new and why it matters in just 5 minutes.
Catch up on the day’s biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider’s guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Pfizer CEO Albert Bourla. Photo: Steven Ferdman/Getty Images
Pfizer’s COVID-19 vaccine generated $3.5 billion in revenue in the first quarter of 2021, which was nearly a fourth of the company’s $14.6 billion income during the period, the pharmaceutical giant reported in an earnings call Tuesday.
Why it matters: The vaccine was the biggest source of revenue for Pfizer — which, unlike some of its competitors — elected to collect the profit from sales of its vaccine, the New York Times notes.
- Pfizer’s operational revenues grew by 8% in the first few months of the year.
- Also unlike some of its competitors, the company did not to take federal funds from the Trump administration’s Operation Warp Speed.
The big picture: Pfizer’s vaccine “is disproportionately reaching the world’s rich” the New York Times reports, citing broad figures from the World Health Organization.
- Vaccines produced by China, India and Russia have become the primary source of doses delivered to poorer nations.
- Pfizer announced Tuesday it has shipped 430 million doses of the vaccine to 91 countries and territories around the world, though it did not specify how much have gone to developing nations.
No comments:
Post a Comment